Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994

European Journal of Cancer

Volumn 35, Issue 5, 1999, Pages 698-706

  Greil, R ^a   Holzner, B ^b   Kemmler, G ^b   Kopp, M ^b   Buchowski, A ^a   Oberaigner, W ^d   Fritsch, E ^b   Dirnhofer, S ^b   Rueffer, U ^c   Diehl, V ^c   Sperner Unterweger, B ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c UNIVERSITY OF COLOGNE   (Germany)

^d NONE

Author keywords

EORTC QLQ C30; Hodgkin's disease; Quality of life assessment; Randomised clinical trials; Self report questionnaires; Therapy modalities

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; INFANT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0033042177     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00025-8     Document Type: Article

References (61)

1. Jacobs E.M., Peters F.C., Luke J.K., et al. Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease. Cancer Chemother. Rep. 27:1963;27-32.
2. Henry-Amar M., Somers R. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. Semin. Oncol. 17:1990;758-768.
3. DeVita V.T.J., Simon R.M., Hubbard S.M., et al. Curability of advanced Hodgkin's disease with chemotherapy. Ann. Intern. Med. 92:1980;587-595.
4. Santoro A., Bonadonna G., Bonfante V., Valaguss P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N. Engl. J. Med. 306:1982;770-775.
5. Boivin J.F., Gutchison G.B., Lubin J.H., Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer. 69:1992;1241-1247.
6. Kaplan H. Hodgkin's Disease. Cambridge, Harvard University Press, 1980.
7. Huguley C.M., Durant J.R., Moores R.R., Chan Y.K., Dorfman R.F., Johnson L. A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) vs nitrogen mustard in advanced Hodgkin's disease. Cancer. 36:1975;1227-1240.
8. British National Lymphoma Investigation Group, BNLI. Value of prednisone in combination chemotherapy of stage IV Hodgkin's disease. Br Med J 1975, 3, 413-414.
9. DeVita V.T.J., Hubbard S.M., Longo D.L. The chemotherapy of lymphomas: looking back, moving forwardthe Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res. 47:1987;5810-5824.
10. Haybittle J.L., Easterling M.J., Bennett M.H., et al. Reviews of British National Lymphoma investigation studies of Hodgkin's disease and development of prognostic index. Lancet. 1:1985;967-972.
11. Kaldor J.M., Day N.E., Clarke E.A., et al. Leukemia following Hodgkin's disease. N. Engl. J. Med. 322:1990;7-13.
12. Hancock S.L., Tucker M.A., Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 270:1993;1949-1955.
13. Byrne J., Fears T.R., Gail M.H., et al. Early menopause in long-term survivors of cancer during adolescence. Am. J. Obstet. Gynecol. 166:1992;788-793.
14. Anselmo A.P., Cartoni C., Bellantuono P., Maurizi-Enrici R., Aboulkair N., Ermini M. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica. 75:1990;155-158.
15. Marmor D., Elefant E., Danchez C., Roux C. Semen analysis in Hodgkin's disease before the onset of treatment. Cancer. 57:1986;1986-1987.
16. Olweny C.L., Juttner C.A., Rofe P., et al. Long-term effects of cancer treatment and consequences of cure: cancer survivors enjoy quality of life similar to their neighbours. Eur. J. Cancer. 29A:1993;826-830.
17. Kornblith A.B., Anderson J., Cella D.F., et al. Quality of life assessment of Hodgkin's disease survivors: a model for cooperative clinical trials. Oncology Huntingt. 4:1990;93-101.
18. Carde P. Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments? Leuk. Lymphoma. 15:(Suppl.1):1995;31-40.
19. Moreau P., Milpied N., Mechinaud-Lacroix F., et al. Early intensive therapy with autotransplantation for high-risk Hodgkin's disease. Leuk. Lymphoma. 12:1993;51-58.
20. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life-instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85:1993;365-376.
21. Lukes R., Craver L., Hall T., Rappaport H., Ruben P. Report of the nomenclature committee. Cancer Res. 26:1966;1311-1320.
22. MacLennan K., Bennett M., Tu A., et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. Cancer. 64:1989;1686-1693.
23. Tura S., Mozzo P., Zinzani P.L., et al. Hodgkin's disease (HD): a historical perspective. Eur. J. Cancer. 22A:1986;1315-1323.
24. Carbone P.P., Paplan H.S., Musshoff K., et al. Report of the committee on Hodgkin's disease staging. Cancer Res. 31:1971;1860-1861.
25. Dühmke E., Diehl V., Loeffler M., et al. Randomized trial with early stage Hodgkin's disease testing 30 gy vs 40 gy extended field radiotherapy alone. Int. J. Radiat. Oncol. Biol. Phys. 36:(2):1996;305-310.
26. Sieber U., Rueffer U., Tesch H., et al. Rapidly alternating COPP+ABV+IMEP (CAI) is equally effective as alternating COPP+ABVD (CA) for Hodgkin's disease: final results of two randomized trials for intermediate (HD5 protocol) and advanced (HD6 protocol) stages. Leuk. Lymphoma. 29:(Suppl. 1):1998;27.
27. Diehl V. Dose-escalated study for the treatment of Hodgkin's disease. The German Hodgkin-Study Group (GHSG). Ann. Hematol. 66:(3):1993;139-140.
28. van Tulder M.W., Aaronson N.K., Bruning P.F. The quality of life of long-term survivors of Hodgkin's disease. Ann. Oncol. 5:1994;153-158.
29. Cox DR, Oakes D. Analysis of Survival Data. New York, Chapman and Hall, 1984.
30. Ferrell B.R., Dow K.H., Leigh S., Ly J., Gulasekaram P. Quality of life in long-term cancer survivors. Oncol. Nurs. Forum. 22:1995;915-922.
31. Gotay C.C., Muraoka M.Y. Quality of life in long-term survivors of adult onset cancers. J. Natl. Cancer Inst. 90:(9):1998;656-676.
32. Kornblith A.B., Anderson J., Cella D.F., et al. Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. Cancer. 70:1992;2214-2224.
33. Devlen J., Maguire P., Phillips P., Crowther D. Psychological problems associated with diagnosis and treatment of lymphomas. II. Prospective study. Br. Med. J. 295:1987;955-957.
34. Chao N.J., Tierney D.K., Bloom J.R., et al. Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood. 80:1992;825-830.
35. Mauch P.M., Kalish L.A., Marcus K.C., et al. Long-term survival in Hodgkin's disease. Relative impact of mortality, second tumors, infection and cardiovascular disease. Cancer J. Sci. Am. 1:1995;33-42.
36. Straus D.J., Gaynor J.J., Myers J., et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J. Clin. Oncol. 8:1990;1173-1186.
37. Erdkamp F.L., Breed W.P., Bosch L.J., Wijnen J.T., Blijham G.B. Hodgkin's disease in the elderly. Cancer. 70:1992;830-834.
38. Walker A., Schoenfeld E.R., Lowman T., Mettlin C.J., MacMillan J., Grufferman S. Survival of the older patient compared with the younger patient with Hodgkin's disease. Cancer. 65:1990;1635-1640.
39. Roach I.M., Brophy N., Cox R., Varghese A., Hoppe R.T. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J. Clin. Oncol. 8:1990;623-629.
40. Guinee V.F., Giacco G.G., Durand M., et al. The prognosis of Hodgkin's disease in older adults. J. Clin. Oncol. 9:1991;947-953.
41. Van Leeuwen F., Klokman W., Hagenbeek A., et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J. Clin. Oncol. 12:1994;312-325.
42. Austin-Seymour M.M., Hoppe R.T., Cox R.S., Rosenberg S.A., Kaplan H.S. Hodgkin's disease in patients over sixty years old. Ann. Intern. Med. 100:1984;13-18.
43. Pocock SJ. Clinical Trials: a Practical Approach. New York, Wiley, 1983.
44. Bonadonna G., Valagussa D. Influence of clinical trials on current treatment strategy for Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;209-218.
45. Gough I.R., Dalgleish L.I. What value is given to quality of life assessment by health professionals considering response to chemotherapy for advanced cancer? Cancer. 68:1991;220-225.
46. Taylor K.M., Feldstein M.L., Skeel R.T., Pandya K.J., Ng P., Carbone P.P. Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J. Clin. Oncol. 12:1994;1796-1805.
47. Freidman M.A., Cain D.F. National Cancer Institute sponsored cooperative group clinical trials. Cancer. 65:1990;2376-2382.
48. McQuellon R.P., Muss H.B., Hoffmann S.L., Russell G., Craven B., Yellen S.B. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J. Clin. Oncol. 13:1995;858-868.
49. Specht L., Gray R.G., Clarke M.J., Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J. Clin. Oncol. 16:(3):1998;830-843.
50. DeVita V.T., Hubbard S.M., Longo D.L. Treatment of Hodgkin's disease. J. Natl. Cancer Inst. 10:1990;19.
51. Carde P., MacKintosh R., Rosenberg S.A. A dose and time response analysis of treatment of Hodgkin's disease with MOPP therapy. J. Clin. Oncol. 1:1983;146-153.
52. Gerhartz H.H., Schwenke H., Bazarbashi S., et al. Randomized comparison of COPP/ABVD vs dose- and time escalated COPP/ABVD with GM-CSF support for advanced Hodgin's disease. Blood. 92:(Suppl. 1, part 1):1998;315a.
53. Diehl V., Franklin J., Sieber M., et al. Increased efficacy through moderate dose escalation of chemotherapy: interim report from the HD9 randomised trial for advanced Hodgkin's disease. Blood. 92:(Suppl. 1):1998;485a.
54. Weijer C., Freedman B., Fuks A., Robbins J., Shapiro S., Skrutkowska M. What difference does it make to be treated in a clinical trial? A pilot study. Clin. Invest. Med. 19:(3):1996;179-183.
55. Karjalainen S., Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. Br. Med. J. 299:1989;1069-1072.
56. Davis S., Wright P.W., Schulman S.F., et al. Participants in randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer. 56:1985;1710-1718.
57. Calane R., Schwaale J.G., Turrisi A.T., Webber B.C., Muggia F. Pulmonary toxicity after irradiation and bleomycin: a review. Radiat. Oncol. Biol. Phys. 5:1979;1513-1518.
58. Mitchell EP, Schein PS. Gastrointestinal toxicity of chemotherapeutic agents. In Perry MC, ed. The Chemotherapy Source Book. Baltimore, Williams & Wilkins, 1992, 620-635.
59. Carde P., Hagenbeek A., Hayat M. Clinical staging versus laparatomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer lymphoma cooperative group. J. Clin. Oncol. 11:1993;2258-2272.
60. Tubiana M., Henry-Amar M., Carde P., et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease: the EORTC Lymphoma Group controlled clinical trials: 1984-1987. Blood. 73:1989;47-56.
61. Koocher GP, O'Malley JE. The Damocles Syndrome: Psychosocial Consequences of Surviving Childhood Cancer. New York, McGraw-Hill, 1981.